In nonsecretory, oligo-secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti-MM agents.
Keywords: disease progression; extramedullary relapse; multiple myeloma; serological markers; serum free light chains.
© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.